AL 112
Alternative Names: AL-112Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Althera Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders in USA
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Metabolic-disorders in USA
- 30 Mar 2021 AL 112 is available for licensing as of 30 Mar 2021. https://www.altherapharma.com/copy-of-contact-us